A Pilot, Open-Label Phase II Study of Sorafenib Combined with Cisplatin Plus Gemcitabine for the Treatment of Patients with Advanced Renal Collecting Duct Carcinoma.
Xi Nan Shang,Chuan Liang Cui,Zhihong Chi,Lu Si,Si Ming Li,Li,Bin Lian,Bi Xia Tang,Xuan Wang,Yan Kong,Xiaodong Xie,Fang-Jian Zhou,Jian-Iln Yuan,Qiang Wei,Jun Guo
DOI: https://doi.org/10.1200/jco.2014.32.15_suppl.e15554
IF: 45.3
2014-01-01
Journal of Clinical Oncology
Abstract:e15554 Background: Collecting duct carcinoma (CDC) of the kidney is a rare and aggressive neoplasm without any approved treatment. The anti-VEGF drugs can produce definite efficacy on renal clear cell carcinoma, but it is limited for advanced CDC. This study was designed to evaluate the efficacy and safety of sorafenib combined with cisplain plus gemcitabine in patients with advanced CDC without prior systemic chemotherapy or anti-VEGF therapy. Methods: This study is an open-label, multicenter, single-arm phase II trial. Up to 20 adult patients with metastatic, recurrent, or unresectable RCC of any MSKCC prognosis and histological confirmation of CDC, ≥1 measurable baseline lesion as per RECIST criteria, ECOG PS ≤2, and adequate liver, renal, and bone marrow function are targeted for enrollment. All patients received sorafenib (400mg Bid) combined with cisplatin plus gemcitabine (cisplatin: 25mg/m2, D1-3; gemcitabine: 1000 mg/m2, D1-8, for 4 cycles) until disease progression, unacceptable toxicity, or study discontinuation for any other reason. The primary study endpoint is PFS. Overall survival, disease control rate, and safety will also be assessed. Results: The first patient visit was June 1, 2012; 12 patients have entered the study to date. 11 patients received prior nephrectomy. The sites of metastases included lung (5/12), mediastinal lymph node(4/12), local recurrence (4/12), retroperitoneal lymph node (4/12), skeleton(2/12) and peritoneum (2/12). The overall objective response rate was 33.3% (95% confidence interval [CI, 6.6% to 59.9%]), with 0(0%) complete response (CR) and 4 (33.3%) partial responses (PRs). 6 (50.0%) had stable disease (SD), and 2(16.7%) had progression disease (PD). The disease control rate was 83.3%. The median progression-free survival was 10 months. The therapy was well tolerated with grade 3-4 toxicities: neutropenia (4/12), thrombocytopenia (3/12), hand-foot syndrome (3/12). Conclusions: Sorafenib combined with cisplatin plus gemcitabine may benefit patients with advanced CDC. More patients will enroll in the next years. Clinical trial information: NCT01762150.